v3.25.0.1
DIVESTITURES AND ACQUISITIONS (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Provisional Amounts of the Assets Acquired and Liabilities Assumed and Consideration Paid and Provisional Amounts of the Assets Acquired
The following table summarizes the consideration paid for HRA Pharma and the provisional amounts of the assets acquired and liabilities assumed (in millions):

HRA Pharma
Purchase Price$1,945.6 
Assets Acquired:
Cash and cash equivalents$44.2 
Accounts receivable 78.1 
Inventories48.3 
Prepaid expenses and other current assets16.6 
Property, plant and equipment 4.6 
Operating lease assets9.7 
Goodwill 559.5 
Definite-lived intangible assets:
Trademarks and trade names1,124.0 
Developed product technology185.1 
Distribution networks 84.4 
Indefinite lived intangibles:
In-process research and development 52.7 
Total intangible assets 1,446.2 
Deferred income taxes12.4 
Other non-current assets0.8 
Total assets2,220.4 
Liabilities assumed:
Accounts payable$43.4 
Payroll and related taxes16.1 
Accrued customer programs 9.0 
Other accrued liabilities 8.9 
Accrued income taxes0.5 
Deferred income taxes186.2 
Other non-current liabilities 10.6 
Total liabilities274.7 
Non-Controlling Interest 0.1 
Net Assets Acquired $1,945.6 
The following table summarizes the consideration paid and provisional amounts of the assets acquired (in millions):

Gateway
Purchase price paid$110.0 
Assets acquired:
Inventories$29.8 
Property, plant and equipment61.5 
Distribution and license agreements and supply agreements14.0 
Customer relationships and distribution networks4.7 
Total intangible assets$18.7 
Net assets acquired$110.0 
Schedule of Pro Forma Impact of Business Combinations The following table presents the unaudited pro forma information as if the acquisitions had been combined with the results reported in our Consolidated Statements of Operations for all periods presented (in millions):
Year Ended
(Unaudited)December 31, 2022
Net sales$4,745.9 
Income (loss) from continuing operations
$(9.6)